Search
for
Sort by
Research 361–390 of 519
- Updates From 2021 Virtual Dermatology Nurses' Association Convention
- Drug Armamentarium for alopecia areata
- Proceedings of the Ninth World Congress for Hair Research (2015)
- Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib
- Skin Pigmentation Types, Causes and Treatment—A Review
- A Comprehensive Review on Skin Pigmentation-Types, Causes, and Treatment
- Predominant expression of interleukin (IL)‐17 in chronic alopecia areata compared to IFN‐γ in pathogenic Th17 cells, tissue‐resident memory T cells and natural killer cells
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study
- Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives
- Evolving CRBN ligands enhance the drug-like properties of protein degraders
- COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
- Recent Advances in Understanding of the Etiopathogenesis, Diagnosis, and Management of Hair Loss Diseases
- Alopecia areata: a review of diagnosis, pathogenesis and the therapeutic landscape
- Alopecia areata – Aktuelles Verständnis und Management
- Efficacy and safety of ritlecitinib, an oral JAK3/TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
- 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- UHPLC-Q-Orbitrap HRMS-based Metabolomics and In Silico Studies on 5-α-Reductase, JAK1, JAK2, and JAK3 of <i>Albizia saponaria</i> L.: Application to Alopecia
- 63418 JAK3/TEC kinase pathways are active in alopecia areata lesions, and their inhibition with Ritlecitinib prevents αCD3/αCD28+IL-2 induced immune privilege collapse in healthy hair follicles ex vivo
- Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
- 695 Selectively targeting JAK1 or JAK3 pathway is sufficient to reverse alopecia areata
- 69 Risk-benefit appraisal of systemic JAK inhibitors for alopecia areata: a comprehensive meta-analysis assessing safety and adverse effects
- Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the ALLEGRO phase 2b/3 randomized, double‐blind, placebo‐controlled trial
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
- Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program
- SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- 0975 Single-cell transcriptomic profiling reveals distinct immunopathogenic programs in alopecia totalis/universalis compared to patchy alopecia areata